Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp online chat

	NCI Highlights


	Maintenance Rituximab for Follicular Lymphoma Azacitidine Improves Survival in MDS Second Stem Cell Transplant Not Helpful in Myeloma

Benefit of Lidocaine Perfusion in Cancer Related Visceral Pain Resistant to Morphinics

Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information

Basic Trial Information

Phase Type Status Age Sponsor Protocol IDs
Phase III Supportive care Active 6 to 70 Other LIDODOULABDO
CSET 2003/1054, NCT00181012

Trial Description

Summary

This study will evaluate the benefit of lidocaine perfusion in cancer related visceral pain resistant to morphinics. It is an efficacy study in adults and children and a randomized prospective study.

Eligibility Criteria

Inclusion Criteria:

Patients suffering from cancer of any type, at any stage, hospitalized at the Institut Gustave Roussy

Aged from 6 to 14 years old (group A) and from 15 to 70 years old (adults)

Presenting visceral pain due to neurotoxic chemotherapy, due to the tumoral mass or to peritoneal carcinosis

Pain resistant to morphinic treatment

Exclusion Criteria:

Cardiac troubles, clinical cardiac insufficiency, or history of myocardial infarction (MI) of less than 3 months

Neurological: non-controlled epilepsy, encephalopathy, or dementia

Severe hepatic insufficiency

Severe renal insufficiency

Respiratory insufficiency

Patients having surgery or in postoperative period

Known deficit in G6PD, alanine exposure, or sulphamide treatment

Porphyria

Weight > 80 kg

Trial Contact Information

Trial Lead Organizations/Sponsors

Institut Gustave Roussy

Philippe Poulain, MD

Principal Investigator

Philippe Poulain, MD		Ph: 33 1 42 11 40 53
		Email: poulain@igr.fr

Trial Sites

France

Villejuif

Institut Gustave Roussy

Philippe Poulain, MD Ph: 33 1 42 11 40 53

Email: poulain@igr.fr

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00181012
Information obtained from ClinicalTrials.gov on March 18, 2009

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.